Pharmacokinetics and Tolerability of the Novel Oral Prostacyclin IP Receptor Agonist Selexipag

Documenti analoghi

• Effect of lopinavir/ritonavir on the pharmacokinetics of selexipag an oral prostacyclin receptor agonist and its active metabolite in healthy subjects
  di: Kaufmann, Priska, et al.
  Pubblicazione: (2015)
• Pharmacokinetics of the novel oral prostacyclin receptor agonist selexipag in subjects with hepatic or renal impairment
  di: Kaufmann, Priska, et al.
  Pubblicazione: (2016)
• A thorough QT study in the context of an uptitration regimen with selexipag, a selective oral prostacyclin receptor agonist
  di: Hoch, Matthias, et al.
  Pubblicazione: (2014)
• Effect of gemfibrozil and rifampicin on the pharmacokinetics of selexipag and its active metabolite in healthy subjects
  di: Bruderer, Shirin, et al.
  Pubblicazione: (2017)
• First-in-child use of the oral selective prostacyclin IP receptor agonist selexipag in pulmonary arterial hypertension
  di: Geerdink, Lianne M., et al.
  Pubblicazione: (2017)